Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
J. bras. econ. saúde (Impr.) ; 13(1): 66-77, Abril/2021.
Artigo em Português | LILACS, ECOS | ID: biblio-1252730

RESUMO

Objetivo: Reunir e sintetizar evidências atuais que avaliem serviços farmacêuticos (SFs) na hipertensão, do ponto de vista econômico. Métodos: Foi realizada uma revisão sistemática de artigos publicados de 2009 a setembro de 2020 no PubMed, Scopus, Lilacs e Cochrane, seguindo o PRISMA. Dois revisores fizeram a triagem, selecionaram independentemente os estudos, extraíram os dados e avaliaram o risco de viés. Resultados: Um total de 2.223 artigos, excluindo duplicatas, foi encontrado nas bases de dados. Após a análise dos critérios de inclusão e exclusão, 12 estudos foram inclusos; oito eram experimentais e quatro observacionais. Os SFs foram conduzidos em farmácias comunitárias, clínicas privadas e hospitais, com intervenções realizadas apenas por farmacêuticos ou em colaboração com outros profissionais. As intervenções, em sua maioria, foram consideradas custo-efetivas, melhorando parâmetros clínicos e a qualidade de vida. Apenas um estudo não apresentou resultados significativos em relação ao cuidado usual. Conclusão: Os SFs foram associados a impactos econômicos positivos, e as intervenções reduziram significativamente custos diretos médicos. No entanto, há necessidade de desenvolvimento de pesquisas mais robustas, como estudos randomizados e controlados, a fim de permitir avaliação mais assertiva quanto à relação de custo-efetividade dos serviços farmacêuticos


Objective: To gather and synthesize current evidence that evaluates Pharmaceutical Services in hypertension, from an economic point of view. Methods: A systematic review of articles published from 2009 to September 2020 in PubMed, Scopus, Lilacs and Cochrane was carried out, following PRISMA guideline. Two reviewers screened and selected independently of the studies, extracted the data and assessed the risk of bias. Results: 2,223 articles excluding duplicates were found in the databases. After analyzing the inclusion and exclusion criteria, 12 studies were included, 8 were experimental and 4 were observational. The PS was performed in community pharmacies, outpatient clinics and hospitals, with interventions performed only by pharmacists or in collaboration with other professionals. Most of the interventions were cost-effective, improving clinical parameters and improving the quality of life. Only one intervention did not show significant results in relation to usual care. Conclusion: PS have been associated with positive economic impacts and interventions have significantly reduced direct medical costs. However, there is a need to develop more robust research, such as randomized and controlled studies, in order to allow a more assertive assessment regarding the cost-effectiveness of pharmaceutical services


Assuntos
Assistência Farmacêutica , Custos e Análise de Custo , Hipertensão
2.
Value Health Reg Issues ; 14: 1-8, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-29254532

RESUMO

OBJECTIVES: To estimate the cost of managing drug-related morbidity (DRM) that leads to visits to the emergency department of a Brazilian hospital. METHODS: This is a cost-of-illness study based on a retrospective cross-sectional analysis of patients' medical records. A questionnaire and analysis of medical records were used to identify patients who were being admitted to the emergency department because of DRM. The direct medical costs of patient management were estimated using a microcosting analysis, and a sensitivity analysis was conducted using the emergency department visit rates due to DRM reported in the literature. RESULTS: Of the total patients interviewed, 14.6% sought emergency care because of DRM and 58.9% were considered preventable. Mean treatment costs were US $900 ± $1,569 (range US $18-$10,847). An extrapolation based on all emergency visits in the last year resulted in annual total treatment costs of US $7.5 million (US $1.1-$1.4 million). It was observed that 39.3% of the total cost of DRM was attributed to adverse drug reactions, 36.9% to nonadherence to treatment, and 16.9% to incorrect dosages. CONCLUSIONS: Adverse drug reactions and nonadherence to treatment are important causes of morbidity and cost to the health service. Much of this resource is spent to treat preventable cases of DRM, which represents a great waste of resources.


Assuntos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/economia , Serviço Hospitalar de Emergência/estatística & dados numéricos , Custos de Cuidados de Saúde/estatística & dados numéricos , Morbidade , Brasil , Estudos Transversais , Serviço Hospitalar de Emergência/economia , Feminino , Hospitalização/economia , Humanos , Masculino , Adesão à Medicação/estatística & dados numéricos , Pessoa de Meia-Idade , Estudos Retrospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA